Patents by Inventor Marilyne BOUROTTE

Marilyne BOUROTTE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11969423
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: April 30, 2024
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Nicolas Willand
  • Patent number: 11903934
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: February 20, 2024
    Assignee: BIOVERSYS AG
    Inventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
  • Publication number: 20230066182
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Application
    Filed: May 27, 2022
    Publication date: March 2, 2023
    Inventors: Glenn E. Dale, Sergio Lociuro, Marc Gitzinger, Stefano Biondi, Marilyne Bourotte
  • Patent number: 11344537
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: May 31, 2022
    Assignee: BIOVERSYS AG
    Inventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
  • Patent number: 11254689
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 22, 2022
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Nicolas Willand
  • Patent number: 11253499
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by Mycobacterium, such as tuberculosis.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: February 22, 2022
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther Porras De Francisco, Modesto Jesús Remuiñan-Blanco, Marilyne Bourotte, Benoit Deprez, Geoffroy Dequirez, Nicolas Willand
  • Publication number: 20220024928
    Abstract: The present invention relates to a compound according to formula (I), wherein R1 and R5 are independently selected from H, halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, —Cn-alkyl-N(R12)(R13) with n=0-3, —Cn-alkyl-C(O)N(R12)(R13) with n=0-3, —SO2—N(R14)-C(O)—R15; —Cn-alkyl-N(R14)-C(O)—R15 with n=0-3, —Cn-alkyl-C(O)—OR16 with n=0-3, —O(C1-C3-alkyl-O)m—C1-C3-alkyl-OR10 with m=0-3, —Cn-alkyl-OR16 with n=0-3, —NH—Cn-alkyl-R18 with n=0-3; —O—Cn-alkyl-R18 with n=0-3; —OPO(OR10)2, —PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R3 is selected from halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, —Cn-alkyl-N(R12)(R13) with n=0-3, —Cn-alkyl-C(O)N(R12)(R13) with n=0-3, —SO2—N(R14)-C(O)—R15; —Cn-alk
    Type: Application
    Filed: November 27, 2019
    Publication date: January 27, 2022
    Inventors: Marilyne BOUROTTE, Michel PIEREN, Sergio LOCIURO, Marc GITZINGER, Christian KEMMER, Birgit SCHELLHORN, Julian SCHILL, Peter SCHNEIDER
  • Publication number: 20210077470
    Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 18, 2021
    Inventors: Sergio Lociuro, Stefano Biondi, Glenn E. Dale, Marilyne Bourotte, Marc Gitzinger
  • Publication number: 20210032268
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Application
    Filed: August 15, 2018
    Publication date: February 4, 2021
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, BIOVERSYS AG
    Inventors: Esther PORRAS DE FRANCISCO, Modesto Jesús REMUIÑAN-BLANCO, Marilyne BOUROTTE, Benoit DEPREZ, Nicolas WILLAND
  • Publication number: 20200253967
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Application
    Filed: August 15, 2018
    Publication date: August 13, 2020
    Inventors: Esther PORRAS DE FRANCISCO, Modesto Jesús REMUIÑAN-BLANCO, Marilyne BOUROTTE, Benoit DEPREZ, Nicolas WILLAND
  • Publication number: 20200170997
    Abstract: The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis.
    Type: Application
    Filed: August 15, 2018
    Publication date: June 4, 2020
    Inventors: Esther PORRAS DE FRANCISCO, Modesto Jesús REMUIÑAN-BLANCO, Marilyne BOUROTTE, Benoit DEPREZ, Geoffroy DEQUIREZ, Nicolas WILLAND